Acadian Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
Other funds holding ORMP
GIA
BCM
Acadian Asset Management's ORMP Position: Q3 2026 in Review
Acadian Asset Management increased its Oramed Pharmaceuticals (ORMP) stake by 294% in Q3 2026, buying an estimated $22.5K and bringing the position to 6,667 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1880.
Acadian Asset Management first reported a position in ORMP in Q2 2023 and has held it in 4 quarters since. The position peaked at $113K in Q2 2023. 93 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.
- Acadian Asset Management held 6,667 shares of Oramed Pharmaceuticals worth $30K as of Q3 2026.
- Acadian Asset Management bought 4,976 Oramed Pharmaceuticals shares in Q3 2026, an estimated $22.5K.
- Oramed Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2026, its #1880 holding.
- Acadian Asset Management first reported a position in Oramed Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
- Acadian Asset Management's Oramed Pharmaceuticals position peaked at $113K in Q2 2023.
- 93 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.
Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.